0.63
-0.0039(-0.62%)
Currency In USD
| Previous Close | 0.63 |
| Open | 0.64 |
| Day High | 0.68 |
| Day Low | 0.58 |
| 52-Week High | 2.95 |
| 52-Week Low | 0.34 |
| Volume | 7.72M |
| Average Volume | 6.66M |
| Market Cap | 26.18M |
| PE | -0.66 |
| EPS | -0.96 |
| Moving Average 50 Days | 0.47 |
| Moving Average 200 Days | 1.24 |
| Change | -0 |
If you invested $1000 in Cognition Therapeutics, Inc. (CGTX) since IPO date, it would be worth $49.34 as of December 21, 2024 at a share price of $0.63. Whereas If you bought $1000 worth of Cognition Therapeutics, Inc. (CGTX) shares 2 years ago, it would be worth $283.83 as of December 21, 2024 at a share price of $0.63.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies
GlobeNewswire Inc.
Dec 18, 2024 12:22 PM GMT
- Improvements Across Measures of Behavior, Function, Cognition and Movement - - Expediting Plans to Advance CT1812 into Late-Stage Trials - - Full Results to be Presented at International Lewy Body Dementia Conference (ILBDC) - - Cognition Therapeut
Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies
GlobeNewswire Inc.
Nov 26, 2024 12:30 PM GMT
– Topline results in second dementia indication expected to be reported in December 2024 – PURCHASE, N.Y., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodeg
Cognition Therapeutics’ Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer’s Population
GlobeNewswire Inc.
Nov 25, 2024 12:30 PM GMT
- Dramatic 95% Reduction of Cognitive Decline in CT1812-treated Patients with Lower Plasma p-tau217 Correlated with Improvements in Key Indicators of Alzheimer’s Disease Biology - - Findings Support Disease-modifying Potential of CT1812 - PURCHASE, N